Anticoagulation Management

Introduction to Anticoagulation

The American Heart Association recommends a maintenance infusion of 20,000-40,000 units/24 hours via continuous IV infusion for anticoagulation management, and the European Society of Cardiology suggests heart rate control is crucial in mitral stenosis during the bridging period 1, 2

The American College of Cardiology recommends a target APTT of 1.5-2 times normal, equivalent to an anti-factor Xa level of 0.3-0.7 U/mL 1

Patients with severe mitral stenosis are at high risk for thromboembolism, especially with atrial fibrillation, according to the European Heart Society 2
High-risk features for thromboembolism include mechanical heart valves, mitral stenosis, or recent venous thromboembolism (<3 months), which may necessitate bridging therapy 3, 4, 5, 6

The European Heart Society emphasizes that therapeutic anticoagulation is extremely important to avoid complications in high-risk patients 2
Be vigilant for signs of bleeding complications, which occur more frequently with higher heparin doses, as noted by the American Association of Neurological Surgeons 7
The CHA₂DS₂-VASc score can be used to weigh the risk of thromboembolism against bleeding risk in deciding on bridging therapy, as recommended by the American College of Cardiology 8

For patients with mechanical heart valves, which may coexist with mitral stenosis, therapeutic anticoagulation is particularly critical, as recommended by the European Heart Society and the American College of Chest Physicians 2, 4
For patients with atrial fibrillation and high thrombotic risk who require temporary interruption of warfarin, bridging therapy with low-molecular-weight heparin (LMWH) is recommended, though decisions should balance stroke and bleeding risks on an individual basis, as suggested by the American College of Cardiology 9
Patients with mechanical heart valves, recent stroke or TIA within 3 months, CHADS₂ score of 5 or 6, or rheumatic valve disease may require bridging therapy, according to the American Heart Association and the American College of Cardiology 9, 10, 11

The BRIDGE trial demonstrated that absence of bridging was non-inferior to bridging with LMWH for prevention of arterial thromboembolism in most AF patients and significantly decreased bleeding risk, as reported by the American Heart Association 10
Multiple studies have demonstrated increased post-procedural bleeding with bridging therapy, particularly after colonoscopy polypectomy, as reported by the European Society of Gastrointestinal Endoscopy 6
Multiple guidelines now recommend against routine bridging for most patients, as it increases bleeding risk without reducing thromboembolic events, as stated by the American College of Cardiology and other guideline societies 9, 5
The standard protocol for bridging involves discontinuing oral anticoagulant (warfarin) 5 days before the procedure and initiating UFH 3-4 days before the procedure, with an initial dose of 5,000 units by IV injection, followed by continuous infusion of 20,000-40,000 units/24 hours 3
Adjusting the UFH dose to maintain APTT at 1.5-2 times normal and stopping UFH infusion 4-6 hours before the procedure is recommended 3
Low molecular weight heparin (LMWH) can be used as an alternative, with a standard dose of 1mg/kg twice daily or 1.5mg/kg once daily, according to the American College of Cardiology guidelines 12

For dabigatran with reduced renal function (CrCl 30-50 mL/min), last dose should be 5 days before procedure, as recommended by the European Society of Gastrointestinal Endoscopy 6
Direct oral anticoagulants like rivaroxaban have a shorter half-life and do not require bridge therapy with heparin in most cases 3
The perioperative management of rivaroxaban involves suspending it 24-48 hours before the procedure (depending on the risk of bleeding and renal function) and restarting it when hemostasis is adequate 4
DOACs should be withheld for 48 hours before high-risk endoscopic procedures and resumed after adequate hemostasis is achieved, typically within 24-48 hours, as recommended by the Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) 5, 13

Idarucizumab is recommended for emergency reversal of dabigatran, and andexanet alfa can be useful for reversal of rivaroxaban and apixaban in emergency situations, according to the American College of Cardiology 9
For emergency procedures requiring immediate reversal of anticoagulation, 4-factor prothrombin complex concentrate is recommended by the American College of Cardiology 8

Antiphospholipid Syndrome (APS) is a condition that requires careful management to prevent thromboembolic events, with various guidelines providing recommendations for anticoagulation therapy and bridging protocols 14, 15, 6
The American College of Cardiology recommends maintaining continuous anticoagulation without interruption in patients with arterial APS who are not undergoing a procedure or surgery, with regular INR monitoring at least monthly when stable 14
Warfarin remains the preferred anticoagulant for APS patients, although direct oral anticoagulants (DOACs) like apixaban may be associated with higher stroke risk in APS patients, according to the American College of Cardiology and Heart Rhythm Society 13, 16
The American College of Chest Physicians recommends Vitamin K antagonists (VKAs) as first-line therapy, targeting an INR of 2.0-3.0 for most patients with arterial APS 15